Sanofi (ENXTPA:SAN) experienced a 4% decline over the past week despite a largely unchanged market. The recent events, including the FDA approval of Dupixent for a rare skin condition and the signing ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

Presented as part of a late-breaking symposium, results from a new study demonstrate the potential for AI to more accurately identify individuals at risk for type 1 diabetes up to a year before ...

Pediatric health experts call for timely vaccination and stronger public-private partnerships to combat infectious diseases ...

Global capability centres, which employ 2.1 million people, are reshaping global business models in India, powered by ...

Sanofi has made an interesting choice for its new head of R&D, turning to Houman Ashrafian, who has deep expertise in the biopharma industry, but can also draw on his most recent role as managing ...

GSK, its consumer health spin-off Haleon, and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it ...

At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...